Oxford BioDynamics AI Stock Analysis
Want to see GB:OBD full AI Analyst Report?
Oxford BioDynamics (OBD) AI Stock Analysis
Oxford BioDynamics
(LSE:OBD)
The score is held down primarily by weak financial performance—ongoing losses, high leverage, and worsening free cash flow. Technicals are also bearish with price below key moving averages and negative MACD, though near-oversold readings provide a small offset. Valuation adds limited support given the negative P/E and no indicated dividend yield.
Oxford BioDynamics (OBD) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 2.45M
- Dividend Yield
- ―
- Average Volume (3M)
- 52.02M
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 0.10
- Revenue Growth
- 33.37%
- EPS Growth
- 86.41%
- Country
- UK
- Employees
- 37
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Oxford BioDynamics Business Overview & Revenue Model
Company Description
Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is...
How the Company Makes Money
OBD makes money primarily by commercializing and licensing its 3D genome/epigenetic biomarker technology and by selling epigenetic-based diagnostic tests and related services. Key revenue streams include: (1) Product and service revenue from diagnost...
Oxford BioDynamics Financial Statement Overview
Summary
Financials indicate substantial weakness: persistent negative profitability (net margin -10.19%) with negative gross/EBIT margins, high leverage (debt-to-equity 4.58), and deteriorating free cash flow growth (-33.93%). Revenue growth (22.21%) is a positive, but it does not offset losses, leverage, and cash flow pressure.
Income Statement
30NegativeBalance Sheet
25NegativeCash Flow
35Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.20M | 1.09M | 636.00K | 510.00K | 154.00K | 341.00K |
| Gross Profit | -3.31M | -6.15M | 289.00K | 266.00K | 116.00K | -557.00K |
| EBITDA | -8.89M | -9.80M | -10.27M | -9.84M | -6.16M | -6.43M |
| Net Income | -9.87M | -11.15M | -11.57M | -10.83M | -6.71M | -6.68M |
Balance Sheet | ||||||
| Total Assets | 9.09M | 8.09M | 12.11M | 16.13M | 11.34M | 15.38M |
| Cash, Cash Equivalents and Short-Term Investments | 2.51M | 1.39M | 2.83M | 5.25M | 999.00K | 4.34M |
| Total Debt | 4.28M | 5.11M | 5.74M | 6.44M | 6.14M | 6.59M |
| Total Liabilities | 5.84M | 6.97M | 7.75M | 10.07M | 8.76M | 8.69M |
| Stockholders Equity | 3.25M | 1.12M | 4.36M | 6.05M | 2.59M | 6.68M |
Cash Flow | ||||||
| Free Cash Flow | -7.30M | -7.73M | -10.77M | -9.01M | -6.08M | -9.01M |
| Operating Cash Flow | -7.28M | -7.71M | -10.17M | -8.29M | -5.18M | -5.92M |
| Investing Cash Flow | -117.00K | 756.00K | -1.49M | -691.00K | 1.25M | 2.83M |
| Financing Cash Flow | 5.65M | 6.52M | 8.25M | 13.42M | 2.56M | -804.00K |
Oxford BioDynamics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBD, the sentiment is Positive. The current price of 0.12 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.11, and below the 200-day MA of 0.17, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 59.65 is Neutral, neither overbought nor oversold. The STOCH value of 40.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:OBD.
Oxford BioDynamics Peers Comparison
Overall Rating
GB:SBTX59Neutral
GB:IXI55Neutral
GB:APTA46Neutral
GB:GENF42Neutral
GB:FAB40Underperform
GB:OBD40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 59Neutral | GBP 12.31M | -26.39 | -5.25% | ― | 95.16% | 85.60% | |
| 55Neutral | GBP 27.92M | -6.50 | -16.18% | ― | 13.04% | 15.88% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | GBP 12.66M | -12.17 | -46.61% | ― | 28.35% | 57.14% | |
| 42Neutral | GBP 9.81M | -7.50 | 609.63% | ― | ― | 56.00% | |
| 40Underperform | GBP 5.32M | -4.29 | -97.87% | ― | 7.38% | 44.13% | |
| 40Underperform | GBP 15.46M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:OBD | Oxford BioDynamics | 0.12 | -0.17 | -58.93% | |
| GB:IXI | IXICO plc | 12.75 | 1.50 | 13.33% | |
| GB:SBTX | SkinBioTherapeutics plc | 4.75 | -10.75 | -69.35% | |
| GB:FAB | Fusion Antibodies Plc | 4.25 | -8.00 | -65.31% | |
| GB:GENF | Genflow Biosciences Plc | 1.65 | -0.35 | -17.50% | |
| GB:APTA | Aptamer Group Plc | 0.36 | -0.57 | -60.75% |
Oxford BioDynamics Corporate Events
Oxford BioDynamics Extends Vulpes Payment Deadline in £9.15m Placing
NeutralOxford BioDynamics Plc, a 3D genomics-focused biotechnology company listed on AIM, provides precision diagnostic blood tests for prostate cancer and immuno-oncology therapy response, and offers the EpiSwitch Orion cloud platform to help pharma and bi...
Oxford BioDynamics Grants Over 1 Billion Share Options to CEO
PositiveOxford BioDynamics has granted its chief executive Richard Compton 1,008,068,322 share options under its 2016 Employee Share Option Plan, significantly expanding his potential equity exposure. The options, issued in three equal tranches with exercise...
Oxford BioDynamics Platform Links Fatigue Disorders Through Shared Genomic Networks
PositiveOxford BioDynamics has highlighted a new peer-reviewed study led by the University of East Anglia that used its EpiSwitch Orion 3D genomics platform to analyse five fatigue-related conditions, including ME/CFS, long Covid, PTSD, rheumatoid arthritis...
Oxford BioDynamics strengthens board with CEO Richard Compton appointment
PositiveOxford BioDynamics has strengthened its leadership structure with the appointment of Chief Executive Officer Richard Compton to its board as an executive director, following completion of regulatory due diligence. The move further aligns management a...
Oxford BioDynamics Wins Shareholder Backing for Massive AIM Placing
PositiveOxford BioDynamics has confirmed that shareholders approved all resolutions at its General Meeting related to a previously announced placing. The biotech group, which develops personalised diagnostic tests and operates its EpiSwitch Orion 3D genomics...
Oxford BioDynamics strikes first Gulf deal for prostate cancer test with Dubai London Clinics
PositiveOxford BioDynamics has signed a partnership with The Dubai London Clinics & Hospitals Group to make its EpiSwitch PSE prostate cancer blood test available across DLCH’s network in the United Arab Emirates. Under the agreement, blood samples will be c...
Oxford BioDynamics seeks £9.15m lifeline in discounted AIM share placing
NegativeOxford BioDynamics has launched a deeply discounted placing of 9.15 billion new shares at £0.001 per share to raise £9.15 million, alongside issuing broker warrants, with the new equity representing around 68.1% of the enlarged share capital. The pro...
Oxford BioDynamics lands first paid deal for EpiSwitch Orion in UK psoriatic arthritis study
PositiveOxford BioDynamics has signed its first commercial agreement for EpiSwitch Orion, its cloud-based 3D genomics discovery platform, marking the first paid third-party access to the system. The deal sits within OPTIMISE, a UK government-funded translati...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026
